http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005049242-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 |
| filingDate | 2003-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9294b8cd252d38678c5bf9aa2a8c9334 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dc450e2499807eeb527195be422f435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b17f9acbcdb2b6257065190bcd4291af |
| publicationDate | 2005-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2005049242-A1 |
| titleOfInvention | Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors |
| abstract | The present invention includes a group of novel compounds that are demonstrated to potently and selectively inhibit HIV integrase (IN) activity in vitro and to potently inhibit HIV replication in live, cultured cells at non-toxic concentrations. The novel compounds disclosed include 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-L-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-L-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-L-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-L-serine, bis-dicaffeoyl-L-isoserine and 1,4-dicaffeoyl-L-lysine. Tests of integrase inhibitors with 2′,3′-dideoxycytidine, zidovudine and nelfinavir (protease inhibitor) indicated a potent synergy against reverse transcriptase inhibitor resistant virus. The potential benefit from the addition of integrase inhibitors to combination drug therapies is significant. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7998965-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1945208-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1945208-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103408423-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8884034-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9434718-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9782382-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7553873-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7541485-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007088172-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007043066-A1 |
| priorityDate | 2000-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 490.